PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China.\', \'Institute of Global Health and Emergency Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.\', \'Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, P. R. China.\', \'Lianshui County Center for Disease Control and Prevention, Lianshui County, P. R. China.\', \'CanSino Biologics Inc., Tianjin, P. R. China.\', \'Canming Medical Technology Co., Ltd, Shanghai, P. R. China.\', \'Department of Public Health, Southeast University, Nanjing, P. R. China.\', \'Vazyme Biotech Co., Ltd, Nanjing, P. R. China.\', \'Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, P. R. China. cw0226@foxmail.com.\', \'NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China. jszfc@vip.sina.com.\', \'Institute of Global Health and Emergency Pharmacy, China Pharmaceutical University, Nanjing, P. R. China. jszfc@vip.sina.com.\', \'Center for Global Health, Nanjing Medical University, Nanjing, P. R. China. jszfc@vip.sina.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1038/s41591-021-01677-z
?:doi
?:hasPublicationType
?:journal
  • Nature medicine
is ?:pmid of
?:pmid
?:pmid
  • 35087233
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 17.067
?:rankingScore_hIndex
  • 484
is ?:relation_isRelatedTo_publication of
?:title
  • Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all